VIFERON rectal suppositories 500 thousand. ME 10 pcs
Condition: New product
934 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Interferon alfa-2b
Release form
Suppositories
Composition
1 supp. contains: Active substance: interferon alpha-2b human recombinant 500,000 IU. Auxiliary substances: α-tocopherol acetate - 55 mg, ascorbic acid - 8.1 mg, sodium ascorbate - 16.2 mg, disodium edetate dihydrate - 100 μg, polysorbate 80 - 100 μg , base cocoa butter and confectionary fat - up to 1 g.
Pharmacological effect
Interferon alpha-2b human recombinant has pronounced immunomodulatory, antiviral, antiproliferative properties, inhibits the replication of RNA and DNA-containing viruses. The complex composition of drugs (ointment, suppositories, gel) causes a number of additional additional effects: in the presence of antioxidants (tocopherol acetate and / or ascorbic acid), the specific antiviral activity of interferon human recombinant alpha 2b increases, its immunomodulating effect on T and B lymphocytes increases , the level of class A secretory immunoglobulins rises, the level of immunoglobulin E is normalized, the functioning of the endogenous interferon alfa-2b system is restored. Ascorbic acid and alpha-tocopherol acetate, being highly active antioxidants, have anti-inflammatory, membrane-stabilizing, and regenerating properties. The use of the drug VIFERON as part of complex therapy allows to reduce therapeutic doses of antibacterial and hormonal drugs, as well as reduce the toxic effects of this therapy. It was established that when using the drug VIFERON, there are no side effects that occur when parenteral administration of interferon alfa-2b preparations, no antibodies are formed that neutralize the antiviral activity of interferon alpha 2b.
Indications
Acute respiratory viral infections, including influenza, incl. complicated by bacterial infection, pneumonia (bacterial, viral, chlamydia) in children and adults as part of complex therapy; - infectious and inflammatory diseases of newborn children, incl. premature infants, such as meningitis (bacterial, viral), sepsis, intrauterine infection (chlamydia, herpes, cytomegalovirus infection, enterovirus infection, candidiasis, incl.visceral, mycoplasmosis), as part of complex therapy; - chronic viral hepatitis B, C, D in children and adults as part of complex therapy, including in conjunction with the use of plasmapheresis and hemosorption in chronic viral hepatitis expressed activity, complicated by liver cirrhosis; adults in the complex therapy; - primary or recurrent herpetic infection of the skin and mucous membranes, localized form, lay down th and moderate flow, including urogenital form in adults.
Contraindications
Hypersensitivity to any of the components of the drug.
Use during pregnancy and lactation
The drug is approved for use from the 14th week of pregnancy. There are no restrictions for use during lactation.
Dosage and administration
The drug is used rectally. 1 Suppository contains interferon alpha-2b human recombinant as the active substance in the indicated dosages (150 000 IU, 500 000 IU, 1 000 000 IU, 3 000 000 IU). Acute respiratory viral infections, including influenza, in t . h. complicated by bacterial infection, pneumonia (bacterial, viral, chlamydia) in children and adults as part of complex therapy. The recommended dose for adults, including pregnant women and children over 7 years old - Viferon 500 000 ME 1 suppository 2 times / day every 12 hours for 5 hours days. According to clinical indications, therapy can be continued. Children up to 7 years old, incl. newborn and premature with gestational age of more than 34 weeks, prescribed Viferon 150,000 ME and 1 suppository 2 times / day every 12 hours every day for 5 days. According to clinical indications, therapy can be continued. The interval between courses is 5 days. For premature newborns with gestational age of less than 34 weeks, Viferon 150,000 ME and 1 suppository 3 times / day every 8 hours daily for 5 days are prescribed. According to clinical indications, therapy can be continued. The break between courses is 5 days. Infectious and inflammatory diseases of newborns, incl.premature infants, such as meningitis (bacterial, viral), sepsis, intrauterine infection (chlamydia, herpes, cytomegalovirus infection, enterovirus infection, candidiasis, including visceral, mycoplasmosis) as part of complex therapy; Recommended dose for newborns, including . premature with gestational age of more than 34 weeks, - Viferon 150 000 ME daily, 1 suppository 2 times / day every 12 hours. The course of treatment is 5 days.
Side effects
Allergic reactions: rarely - skin rash, itching. These phenomena are reversible and disappear after 72 hours after stopping the drug.
Overdose
Data on drug overdose Viferon not provided.
Interaction with other drugs
Viferon is compatible and well combined with all drugs used in the treatment of the above mentioned diseases (including antibiotics, chemotherapy drugs, GCS).
special instructions
For the treatment of a wide range of infectious and inflammatory diseases, Viferon can be used as part of combination therapy with antibacterial drugs, glucocorticoids, immunosuppressive drugs. toxoplasmosis, cytomegalovirus infection in adults and children older than 1 year; viral hepatitis in adults, SARS, influenza, bronchial asthma, juvenile rheumatoid arthritis; meningeal form of tick-borne encephalitis; prostatitis of various etiologies; purulent-septic postoperative complications, virus-associated glomerulonephritis, pyelonephritis.